HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q2 2021 13F Holders as of 30 Jun 2021

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
129,727,357
Share change
-2,036,817
Total reported value
$5,890,257,760
Put/Call ratio
96%
Price per share
$45.41
Number of holders
309
Value change
-$85,620,767
Number of buys
147
Number of sells
150

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q2 2021

As of 30 Jun 2021, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 309 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 129,727,357 shares. The largest 10 holders included BlackRock Inc., VANGUARD GROUP INC, Artisan Partners Limited Partnership, Invesco Ltd., JPMORGAN CHASE & CO, STATE STREET CORP, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, SNYDER CAPITAL MANAGEMENT L P, MACQUARIE GROUP LTD, and GEODE CAPITAL MANAGEMENT, LLC. This page lists 309 institutional shareholders reporting positions in this security for the Q2 2021 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.